SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2013), Enfermedades Infecciosas y Microbiología Clínica, 2013, 31, 9, 602.e1

    CrossRef

  2. 2
    Claudio Ucciferri, Katia Falasca, Francesca Vignale, Marta Di Nicola, Eligio Pizzigallo, Jacopo Vecchiet, Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy, Journal of Medical Virology, 2013, 85, 5
  3. 3
    José L. Casado, Ignacio de los Santos, María del Palacio, Lucio García-Fraile, María J. Pérez-Elías, Jesús Sanz, Santiago Moreno, Lipid-Lowering Effect and Efficacy After Switching to Etravirine in HIV-Infected Patients With Intolerance to Suppressive HAART, HIV Clinical Trials, 2013, 14, 1, 1

    CrossRef

  4. 4
    Klaus Jansen, Anders Sönnerborg, Norbert Brockmeyer, Anders Thalme, Veronica Svedhem, Stephan Dupke, Jean-Luc Eychenne, Tina Nakonz, Maria Jesus Jimenez-Exposito, Pascal Pugliese, Long-Term Efficacy and Safety of Atazanavir/Ritonavir Treatment in a Real-Life Cohort of Treatment-Experienced Patients with HIV Type 1 Infection, AIDS Research and Human Retroviruses, 2013, 29, 3, 564

    CrossRef

  5. 5
    José L. Casado, Santiago Moreno, Potencial papel de rilpivirina en el escenario de simplificación, Enfermedades Infecciosas y Microbiología Clínica, 2013, 31, 30

    CrossRef

  6. 6
    Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2012), Enfermedades Infecciosas y Microbiología Clínica, 2012, 30, 6, e1

    CrossRef

  7. 7
    L. Ferraris, O. Vigano, A. Peri, M. Tarkowski, G. Milani, S. Bonora, F. Adorni, C. Gervasoni, E. Clementi, G. Di Perri, M. Galli, A. Riva, Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers, Journal of Antimicrobial Chemotherapy, 2012, 67, 9, 2236

    CrossRef

  8. 8
    Christoph Stephan, Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature, Expert Opinion on Pharmacotherapy, 2012, 13, 16, 2355

    CrossRef

  9. 9
    Elena Ferrer, Luis del Rio, Esteban Martínez, Jordi Curto, Pere Domingo, Esteban Ribera, Eugenia Negredo, Joaquim Rosales, Maria Saumoy, Jordi Ordóñez, Josep M. Gatell, Daniel Podzamczer, Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults, AIDS Research and Human Retroviruses, 2011, 27, 10, 1061

    CrossRef